Skip to main content
Figure 5 | World Journal of Surgical Oncology

Figure 5

From: Clusterin confers gmcitabine resistance in pancreatic cancer

Figure 5

Effect of combined treatment with AS clusterin ODN and gmcitabine BxPC-3 cell growth. A, BxPC-3 cells were treated daily with 500 nM AS clusterin ODN or MM control ODN for 2 days. After ODN treatment, the medium was replaced with medium containing various concentrations of gmcitabine. After 48 h of incubation, the number of viable cells was determined by the MTT assay. B, BxPC-3 cells were treated daily with 100, 500, 1000 nM AS clusterin ODN or MM control ODN for 2 days. After ODN treatment, the medium was replaced with medium containing 5 uM concentrations of gmcitabine. After 48 h of incubation, the number of viable cells was determined by the MTT assay. Each data point represents the mean of triplicate analyses with SD. ** and *, differs from controls (P < 0.01 and P < 0.05, respectively) by Student's t test.

Back to article page